HU-210

From Wikipedia, the free encyclopedia

Jump to: navigation, search
HU-210
Systematic (IUPAC) name
(6aR,10aR)- 9-(Hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo [c]chromen- 1-ol
Identifiers
CAS number 112830-95-2
ATC code  ?
PubChem 9821569
Chemical data
Formula C25H38O3 
Mol. mass 386.567 g/mol
Synonyms 1,1-Dimethylheptyl- 11-hydroxy- tetrahydrocannabinol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status

Schedule I (USA)

Routes  ?

HU-210 is a synthetic cannabinoid that was first synthesized in 1988 by the group led by Professor Raphael Mechoulam at the Hebrew University.[1][2][3] HU-210 is 100 to 800 times more potent than natural THC from cannabis and has an extended duration of action.[4] HU-210 is the (–)-1,1-dimethylheptyl analog of 11-hydroxy- Δ8- tetrahydrocannabinol, in some references it is called 1,1-dimethylheptyl- 11-hydroxytetrahydrocannabinol. The abbreviation HU stands for Hebrew University.

Per a 2005 article in the Journal Of Clinical Investigation, HU-210 with daily high doses over a few weeks stimulates neural growth in rats' hippocampus region. It was also indicated by this increased neural growth to entail antianxiety and antidepressant effects.[5]

HU-210, alongside other synthetic cannabinoids like WIN 55,212-2 and JWH-133, is implicated in preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers. This anti-inflammatory action is induced through the activation of cannabinoid receptors which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids completely abolish neurotoxicity related to microglia activation in rat models.[6]

HU-210 is a potent analgesic with many of the same effects as natural THC.

Contents

[edit] Illicit use

According to the U.S. Customs and Border Protection, HU-210 was discovered in Spice Gold products seized at the US border in January 2009. Over 100 pounds of Spice products were seized based on this finding,[7]. HU-210 was also detected in three Spice products in the UK, as reported in June 2009.[8].

[edit] See also

[edit] References

  1. ^ Mechoulam, R; Feigenbaum; Lander; Segal; Järbe; Hiltunen; Consroe (1988). "Enantiomeric cannabinoids: stereospecificity of psychotropic activity". Experientia 44 (9): 762–4. doi:10.1007/BF01959156. PMID 3416993.  edit
  2. ^ Little PJ, Compton DR, Mechoulam R, Martin BR. Stereochemical effects of 11-OH-Δ8-THC-dimethylheptyl in mice and dogs. Pharmacology, Biochemistry, and Behavior. 1989 Mar;32(3):661-666.
  3. ^ Järbe, TU; Hiltunen; Mechoulam (1989). "Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons". The Journal of pharmacology and experimental therapeutics 250 (3): 1000–5. PMID 2550611.  edit
  4. ^ Devane, WA; Breuer; Sheskin; Järbe; Eisen; Mechoulam (1992). "A novel probe for the cannabinoid receptor". Journal of medicinal chemistry 35 (11): 2065–9. doi:10.1021/jm00089a018. PMID 1317925.  edit
  5. ^ Jiang, W.; Zhang, Y.; Xiao, L.; Van Cleemput, J.; Ji, S.; Bai, G.; Zhang, X. (2005). "Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects". The Journal of clinical investigation 115 (11): 3104–3116. doi:10.1172/JCI25509. PMID 16224541.  edit
  6. ^ Ramírez, B.; Blázquez, C.; Gómez Del Pulgar, T.; Guzmán, M.; De Ceballos, M. (2005). "Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation". The Journal of neuroscience : the official journal of the Society for Neuroscience 25 (8): 1904–1913. doi:10.1523/JNEUROSCI.4540-04.2005. PMID 15728830.  edit
  7. ^ "Lab Results Confirm CBP in Ohio Discover Synthetic Narcotics in Incense Packets - CBP.gov". http://www.cbp.gov/xp/cgov/newsroom/news_releases/01142009_3.xml. 
  8. ^ "EMCDDA Action on new drugs briefing paper: Understanding the ‘Spice’ phenomenon". http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_EMCDDA_Understanding%20the%20‘Spice’%20phenomenon_1Update%2020090514.pdf. 

[edit] External links


Languages